The Business Research Company’s market reports offer an in-depth analysis on the market’s growth potential, major drivers, key trends and more.

Understanding Market Dynamics

• Rapid growth from $2.32 billion in 2023 to $2.59 billion in 2024.
• Compound annual growth rate (CAGR) of 11.2% attributed to various factors.
• Expansion of cardiac treatment options, improved patient outcomes, among others.

Promising Projections

• Expected growth to $4.01 billion in 2028.
• Compound annual growth rate (CAGR) of 11.6%.
• Factors include growing cardiovascular disease burden, advancements in drug delivery systems.

Read More On The Inotropic Agents Market Report 2024 – https://www.thebusinessresearchcompany.com/report/inotropic-agents-global-market-report

Surging Cardiovascular Diseases Propel Growth In The Inotropic Agent Market

The Cardiovascular Disease Landscape

• Cardiovascular diseases (CVDs) refer to diseases of the vascular system and heart functioning.
• Inotropic agents used to treat CVDs by improving heart contractility and function.
• Prevalence statistics underline the significance of the market’s growth.

Statistics and Insights

• Heart diseases were the leading cause of death in the US in 2020.
• Approximately 697,000 people died from heart disease, accounting for 1 in every 5 deaths.
• About 20.1 million adults suffered from coronary artery disease.
• Each year, about 805,000 people in the US suffer from a heart attack.
• The risk of stroke was expected to increase by 33.8 percent to 15 million from 2025 to 2060.

Bristol-Myers Squibb’s Mavacamten Receives FDA Approval, Setting A Trend In The Inotropic Agents Market

Focus on Drug Approvals

• Bristol-Myers Squibb receives FDA approval for Mavacamten.
• Used in the treatment of class II-III obstructive hypertrophic cardiomyopathy (HCM).
• Inhibits excessive contraction of the heart muscle.
• Selective inhibitor of cardiac myosin, a protein involved in muscle contraction.

Strategic Acquisitions

• Pfizer Inc. acquires Arena Pharmaceuticals Inc. for $6.7 billion.
• Aim to improve cardiovascular treatments and capabilities.
• Arena Pharmaceuticals Inc. specializes in inotropic drugs and cardiovascular drugs.

Segmentation and Regional Insights

Understanding Market Segments

1. By Type: Positive Inotropic Drugs, Negative Inotropic Drugs, Other Types
2. By Route Of Administration: Oral, Parenteral, Other Routes Of Administration
3. By Indication: Heart Attack, Heart Failure, Angina, Arrhythmia, Other Indications
4. By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Other Distribution Channels
5. By End User: Hospital, Homecare, Specialty Centers, Other End Users

Regional Trends

• North America was the largest region in the inotropic agents market in 2023.
• Asia-Pacific expected to be the fastest-growing region during the forecast period.

In conclusion, the inotropic agents market reflects significant growth potential driven by the increasing prevalence of cardiovascular diseases and advancements in drug development. Companies like Bristol-Myers Squibb and Pfizer Inc. are at the forefront of innovation, ushering in new treatment options and expanding the market’s horizons. As the market continues to evolve, segmentation and regional dynamics will play crucial roles in shaping its trajectory, ensuring better outcomes for patients globally.

Request for A Sample Of The Global Inotropic Agents Market Report:
https://www.thebusinessresearchcompany.com/sample_request?id=10711&type=smp